Aldeyra Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing reproxalap, its lead product candidate. The company has submitted a new drug application (NDA) for reproxalap to the FDA and has entered into an exclusive option agreement with AbbVie Inc. Aldeyra is also developing additional product candidates, conducting preclinical and clinical trials, and building commercialization, marketing, and manufacturing capabilities.
Q2 FY2026 — expected 2026-08-15
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-27 | 2025-12-31 | 0001193125-26-083012 | EDGAR | 87K words |
| 2025-02-28 | 2024-12-31 | 0000950170-25-030102 | EDGAR | 86K words |
| 2024-03-07 | 2023-12-31 | 0000950170-24-027933 | EDGAR | 85K words |
| 2023-03-09 | 2022-12-31 | 0000950170-23-006998 | EDGAR | 80K words |
| 2022-03-17 | 2021-12-31 | 0000950170-22-004111 | EDGAR | — |
| 2021-03-11 | 2020-12-31 | 0001564590-21-012501 | EDGAR | — |
| 2020-03-12 | 2019-12-31 | 0001564590-20-010493 | EDGAR | — |
| 2019-03-08 | 2018-12-31 | 0001564590-19-006997 | EDGAR | — |
| 2018-03-29 | 2017-12-31 | 0001193125-18-102077 | EDGAR | — |
| 2017-03-30 | 2016-12-31 | 0001193125-17-104228 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-06 | 2026-06-30 | 0001341235-26-000010 | EDGAR | 57K words |
| 2025-11-05 | 2025-09-30 | 0001193125-25-266989 | EDGAR | 59K words |
| 2025-08-07 | 2025-06-30 | 0000950170-25-104971 | EDGAR | 59K words |
| 2025-05-14 | 2025-03-31 | 0000950170-25-071602 | EDGAR | 58K words |
| 2024-11-07 | 2024-09-30 | 0000950170-24-123248 | EDGAR | 58K words |
| 2024-08-01 | 2024-06-30 | 0000950170-24-089238 | EDGAR | 58K words |
| 2024-05-02 | 2024-03-31 | 0000950170-24-052056 | EDGAR | 57K words |
| 2023-11-03 | 2023-09-30 | 0000950170-23-058829 | EDGAR | 58K words |
| 2023-08-03 | 2023-06-30 | 0000950170-23-037934 | EDGAR | 55K words |
| 2023-05-04 | 2023-03-31 | 0000950170-23-017827 | EDGAR | 53K words |
| 2022-11-10 | 2022-09-30 | 0000950170-22-024434 | EDGAR | — |
| 2022-08-05 | 2022-06-30 | 0000950170-22-015115 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-07-30 | 0001193125-26-326337 | EDGAR | 1K words |
| 2026-07-15 | 0001193125-26-304880 | EDGAR | 1K words |
| 2026-04-01 | 0001193125-26-137984 | EDGAR | 1K words |
| 2026-03-17 | 0001193125-26-109511 | EDGAR | 1K words |
| 2025-12-31 | 0001193125-25-338394 | EDGAR | 1K words |
| 2025-12-16 | 0001193125-25-319638 | EDGAR | 1K words |
| 2025-11-13 | 0001193125-25-278804 | EDGAR | 3K words |
| 2025-10-28 | 0001193125-25-252200 | EDGAR | 1K words |
| 2025-08-19 | 0000950170-25-109932 | EDGAR | 1K words |
| 2025-07-17 | 0001213900-25-064869 | EDGAR | 1K words |
267 total filings indexed. 235 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001341235 |
| Ticker | ALDX |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.aldeyra.com |
| Listed | 2014-05-02 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/ALDX (~200 tokens, structured JSON with cryptographic provenance)